DOCSLIB.ORG

US5322694.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
US5322694.Pdf ||||||||||I||US005322694A United States Patent (19) 11 Patent Number: 5,322,694 Sixsmith 45) Date of Patent: Jun. 21, 1994 (54) PHARMACEUTICAL LOZENGES 75 Inventor: David G. Sixsmith, Farnham, FOREIGN PATENT DOCUMENTS England 01.00157 7/1983 European Pat. Off. 0409279 7/1990 European Pat. Off. 73) Assignee: Merrell Dow Pharmaceuticals Inc., 2009597 6/1978 United Kingdom. Cincinnati, Ohio OTHER PUBLICATIONS (21) Appl. No.: 847,856 Gennaro. (1985). Remington's Pharmaceutical Sci 22 Filed: Mar. 9, 1992 ences. Mack Publishing Co., Pa. Oakenfull, D. et al. (1986). Food Hydrocolloids vol. 1, Related U.S. Application Data No. 2, pp. 163-176. 63 Continuation of Ser. No. 625,724, Dec. 10, 1990, aban Acta Pharmaceutica Fennica, vol. 87, No. 2, 1978, pp. doned. 61-73. (30) Foreign Application Priority Data Primary Examiner-Thurman K. Page Assistant Examiner-Raj Bawa Dec. 13, 1989 (GB) United Kingdom ................. 892896 Attorney, Agent, or Firm-Michael J. Sayles 51) Int. Cli................................................ A61K9/20 52 U.S. C. .................................... 424/440; 424/439; (57 ABSTRACT 424/441; 424/464; 424/465; 424/470; 424/488; The present invention is directed to gelatin treated 514/960 polyhydric alcohol compositions, their preparation, and 58) Field of Search ............... 424/440, 439, 441, 464, to pharmaceutical lozenges prepared therefrom. The 424/465, 470, 488; 514/960 pre-granulation of a polyhydric alcohol with an aque (56) References Cited ous gelatin solution prior to compression, produces U.S. PATENT DOCUMENTS lozenges having a delayed rate of dissolution. 4,624,849 11/1986 Toogood .......................... 424/78.01 6 Claims, No Drawings 5,322,694 1 2 which the bulking agent is a polyhydric alcohol. This PHARMACEUTICAL LOZENGES "polyhydric alcohol carrier" may also contain excipi ents commonly used in the preparation of sugar-free This is a continuation of application Ser. No. lozenges. Examples of such excipients include an addi 07/625,724, filed Dec. 10, 1990, now abandoned. 5 tional sugar-free diluent such as mannitol or sorbitol, The present invention is directed to polyhydric alco antiadherants such as colloidal silica, lubricants which hol based lozenges having a delayed rate of dissolution. are known in the art, and flavoring agents known in the Another aspect of the invention is directed to an inert art. polyhydric alcohol based carrier which will produce c) the terms "gelatin treated polyhydric alcohol such lozenges. Another aspect of the invention is di 10 based carrier' or "gelatin treated polyhydric alcohol' rected to a method for producing such a lozenge. should be construed as describing a composition con Lozenges or troches are pharmaceutical dosage taining a polyhydric alcohol and optionally containing forms which are used to treat disease states affecting the other pharmaceutical excipients which has been granu tissues contained within the oral cavity and throat. A lated with a gelatin solution, and optionally dried and typical lozenge or troche is composed predominantly of 15 milled to a particle size suitable for incorporation into an inert vehicle, carrier, or diluent. A medicinal agent is lozenge; interspersed within this carrier. The lozenge will slowly d) the terms "lozenge or troche' are used inter dissolve when placed in the oral cavity thereby releas changeably in this application and refer to a medicated ing the medicinal agent so that it may come in contact tablet or disk which will dissolve in the oral cavity with the tissues of the mouth and throat. These dosage 20 thereby releasing its medication for the treatment of forms are typically used to treat conditions such as tissues within this cavity; throat infections, dental plaque, halotosis, etc. e) the term "lozenge' should be construed as encom Typically the carrier material is a sugar such as su passing only those lozenges which are manufactured by crose, dextrose, etc. Recently consumers have become compression methods and; concerned about the excessive levels of sugar contained 25 f) the terms "carrier, diluent, and vehicle,' are used within their diets. This concern has caused a demand for interchangeably and refer to an inert excipient which sugar-free products, including sugar-free medications. serves primarily as the bulking agent in the lozenge. Pharmaceutical manufacturers have attempted to find Xylitol is one of the polyhydric alcohols which is alternative carrier bases in order to provide sugar-free suitable for use in the present invention. It is also the lozenges. One such alternative carrier is a polyhydric 30 preferred polyhydric alcohol. It is known in the phar alcohol such as xylitol. Polyhydric alcohols are consid maceutical arts as a sweetener. Its chemical name is ered as a viable alternative because they provide a sweet 1,2,3,4,5-pentanpentol. It also has been referred to as taste will mask the bitter taste of many medicinal agents. xylit, xilitol, xylitolo, klinit and pentapentol. This sub Lozenges made from polyhydric alcohols do suffer stance is available from numerous commercial sources, from one serious disadvantage. They dissolve very rap 35 such as, for example, Hoffman La Roche, Esai Co. Ltd., idly when placed in the oral cavity. For example a Finnsugar, and Roquette. Methods of manufacturing lozenge made from a xylitol based carrier will dissolve this substance are taught in the Handbook of Pharma completely within approximately 3 minutes of adminis ceutical Excipients, jointly published by the American tration. Other polyhydric alcohols such as sorbitol or Pharmaceutical Association and The Royal Pharma mannitol will also dissolve within 3 minutes of adminis ceutical Society of Great Britain (1986). tration. Thus the medicinal agents are released so rap Mannitol is known as an excipient. This substance's idly that a large percentage of the dose is washed into chemical name is 1,2,3,4,5,6-hexanehexol. It has been the patients alimentary canal rather than having an referred to as manite, manna sugar, and as manita. This opportunity to come in contact with the tissues of the substance is also available from numerous commercial oral cavity which are under treatment. Thus it would be 45 sources and its method of manufacture is taught in the a valuable contribution to the art to produce polyhydric Handbook of Pharmaceutical Excipients, id. alcohol based lozenges having slower rates of dissolu Sorbitol is also a well known pharmaceutical excipi tion within the oral cavity. ent. It's chemical name is 1,2,3,4,5,6,-hexanehexol. It has The present invention is directed to a polyhydric also been referred to as d-glucitol, d-sorbitol, sorbite, alcohol based carrier which will produce lozenges hav 50 and sorbol. This substance is also available from numer ing decreased rates of dissolution relative to the poly ous commercial sources and its method of manufacture hydric alcohol lozenges currently available. It has been is taught in the Handbook of Pharmaceutical Excipi discovered that if the polyhydric alcohol based carrier ents, id. is granulated with a gelatin solution, any lozenges pro The other polyhydric alcohols which may be utilized duced from this carrier will have a delayed rate of disso 55 in the present invention are maltitol, isomaltitol, malto lution within the oral cavity. It has also been discovered tritol, lactitol, a-l-glucopyranasido-1,6-mannitol, and that the dissolution rates of these lozenges can be fur A-linked-glucopyranasido-sorbitol. These compounds ther delayed if a hydrophobic lubricant is incorporated are also well known in the art as sugar-free substitutes. into the carrier at levels of at least 2 w/w%. For example, see CHEMICAL TECHNOLOGY RE As used in this application: VIEW, No. 30, Tablet Manufacture, Noyes Data Cor a) the term "polyhydric alcohol'should be construed poration, (1974) or SILESIA CONFISERIE MANUAL as describing the following substances: xylitol, manni NO. 3. They are available from numerous commercial tol, sorbitol, maltitol, isomaltitol, maltotritol, lactitol, suppliers, such as, for example, Aldrich, Finnsugar, or a-1-glucopyranasido-l,6-mannitol, and (3-linked Roquette. glucopyranasido-sorbitol. 65 As noted above, one aspect of the present invention is b) the term "polyhydric alcohol carrier" should be directed to a method for producing a gelatin treated construed as describing a diluent, carrier, or vehicle polyhydric alcohol based carrier, which after proper which is suitable for compounding into a lozenge, in compression will produce lozenges having delayed 5,322,694 3 4. rates of dissolution within the oral cavity. This result is lozenges and troches. Methods for producing lozenges by granulating the polyhydric alcohol with a gelatin and troches are well known in the art. Typically a me solution. This treatment should be carried out prior to dicinal agent, and excipients such as anti-adherants, the time at which the carrier is compounded into a flavoring agents, lubricants, etc. are dry blended with dosage form. the carrier and the mixture is then compressed in order This granulation is typically carried out in the follow to produce a lozenge or troche. More detailed descrip ing manner. The powdered polyhydric alcohol is op tions for producing troches and lozenges are taught in tionally dry blended with a dispersing agent such as Pharmaceutical Dosage Forms Vol. 1. The resulting microcrystalline cellulose. The function of the dispers lozenges will take at least 6 minutes to completely dis ing agent is to improve the distribution of the gelatin 10 solve within the oral cavity. through the powdered polyhydric alcohol. Other suit As noted above, the dissolution rate of the lozenge able dispersing agents include starches, untreated cellu can be further delayed if a hydrophobic lubricant is loses and modified celluloses. The quantity of dispers present in the lozenge at levels of at least 2 w/w% and ing agent that is utilized can vary widely. However, the more preferably at a level between 2-10 w/w%, and dispersing agent is generally present in this blend in the 15 quantity of from about 1-20 w/w% and more prefera most preferably about 3 w/w%.
Load more

Recommended publications
  • Antiseptics and Disinfectants for the Treatment Of
    Verstraelen et al. BMC Infectious Diseases 2012, 12:148 http://www.biomedcentral.com/1471-2334/12/148 RESEARCH ARTICLE Open Access Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review Hans Verstraelen1*, Rita Verhelst2, Kristien Roelens1 and Marleen Temmerman1,2 Abstract Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and disinfectants in treating bacterial vaginosis (BV). Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (1970- 2010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A. Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria. Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide was slightly, though significantly less effective than a single oral dose of metronidazole.
    [Show full text]
  • Identification of Candidate Agents Active Against N. Ceranae Infection in Honey Bees: Establishment of a Medium Throughput Screening Assay Based on N
    RESEARCH ARTICLE Identification of Candidate Agents Active against N. ceranae Infection in Honey Bees: Establishment of a Medium Throughput Screening Assay Based on N. ceranae Infected Cultured Cells Sebastian Gisder, Elke Genersch* Institute for Bee Research, Department of Molecular Microbiology and Bee Diseases, Hohen Neuendorf, Germany * [email protected] Abstract OPEN ACCESS Many flowering plants in both natural ecosytems and agriculture are dependent on insect Citation: Gisder S, Genersch E (2015) Identification of Candidate Agents Active against N. ceranae pollination for fruit set and seed production. Managed honey bees (Apis mellifera) and wild Infection in Honey Bees: Establishment of a Medium bees are key pollinators providing this indispensable eco- and agrosystem service. Like all Throughput Screening Assay Based on N. ceranae other organisms, bees are attacked by numerous pathogens and parasites. Nosema apis is Infected Cultured Cells. PLoS ONE 10(2): e0117200. a honey bee pathogenic microsporidium which is widely distributed in honey bee popula- doi:10.1371/journal.pone.0117200 tions without causing much harm. Its congener Nosema ceranae was originally described Academic Editor: Wolfgang Blenau, Goethe as pathogen of the Eastern honey bee (Apis cerana) but jumped host from A. cerana to A. University Frankfurt, GERMANY mellifera about 20 years ago and spilled over from A. mellifera to Bombus spp. quite recent- Received: October 8, 2014 ly. N. ceranae is now considered a deadly emerging parasite of both Western honey bees Accepted: December 20, 2014 and bumblebees. Hence, novel and sustainable treatment strategies against N. ceranae are Published: February 6, 2015 urgently needed to protect honey and wild bees.
    [Show full text]
  • 4. Antibacterial/Steroid Combination Therapy in Infected Eczema
    Acta Derm Venereol 2008; Suppl 216: 28–34 4. Antibacterial/steroid combination therapy in infected eczema Anthony C. CHU Infection with Staphylococcus aureus is common in all present, the use of anti-staphylococcal agents with top- forms of eczema. Production of superantigens by S. aureus ical corticosteroids has been shown to produce greater increases skin inflammation in eczema; antibacterial clinical improvement than topical corticosteroids alone treatment is thus pivotal. Poor patient compliance is a (6, 7). These findings are in keeping with the demon- major cause of treatment failure; combination prepara- stration that S. aureus can be isolated from more than tions that contain an antibacterial and a topical steroid 90% of atopic eczema skin lesions (8); in one study, it and that work quickly can improve compliance and thus was isolated from 100% of lesional skin and 79% of treatment outcome. Fusidic acid has advantages over normal skin in patients with atopic eczema (9). other available topical antibacterial agents – neomycin, We observed similar rates of infection in a prospective gentamicin, clioquinol, chlortetracycline, and the anti- audit at the Hammersmith Hospital, in which all new fungal agent miconazole. The clinical efficacy, antibac- patients referred with atopic eczema were evaluated. In terial activity and cosmetic acceptability of fusidic acid/ a 2-month period, 30 patients were referred (22 children corticosteroid combinations are similar to or better than and 8 adults). The reason given by the primary health those of comparator combinations. Fusidic acid/steroid physician for referral in 29 was failure to respond to combinations work quickly with observable improvement prescribed treatment, and one patient was referred be- within the first week.
    [Show full text]
  • 1 Brief Report: the Virucidal Efficacy of Oral Rinse Components Against SARS-Cov-2 in Vitro Evelina Statkute1†, Anzelika Rubin
    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.13.381079; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Brief Report: The Virucidal Efficacy of Oral Rinse Components Against SARS-CoV-2 In Vitro Evelina Statkute1†, Anzelika Rubina1†, Valerie B O’Donnell1, David W. Thomas2† Richard J. Stanton1† 1Systems Immunity University Research Institute, Division of Infection & Immunity, School of Medicine, Heath Park, Cardiff, CF14 4XN 2Advanced Therapies Group, School of Dentistry, Cardiff University, Heath Park, Cardiff CF14 4XY, UK †These authors contributed equally * Correspondence: [email protected], [email protected] Running title: Virucidal Activity of Mouthwashes Keywords: SARS-CoV2, mouthwash, lipid, envelope Disclosure: Venture Life Group plc provided information on mouthwash formulations employed in the study, but had no role in funding, planning, execution, analysis or writing of this study. A separate study funded to Cardiff University by Venture Life Group is assessing in vivo efficacy of CPC in patients with COVID19. The investigators declare no direct conflicts exist. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.11.13.381079; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license.
    [Show full text]
  • Clioquinol: Summary Report
    Clioquinol: Summary Report Item Type Report Authors Gianturco, Stephanie L.; Pavlech, Laura L.; Storm, Kathena D.; Yoon, SeJeong; Yuen, Melissa V.; Mattingly, Ashlee N. Publication Date 2020-01 Keywords Clioquinol; Compounding; Food, Drug, and Cosmetic Act, Section 503B; Food and Drug Administration; Outsourcing facility; Drug compounding; Legislation, Drug; United States Food and Drug Administration Rights Attribution-NoDerivatives 4.0 International Download date 24/09/2021 22:12:31 Item License http://creativecommons.org/licenses/by-nd/4.0/ Link to Item http://hdl.handle.net/10713/12091 Summary Report Clioquinol Prepared for: Food and Drug Administration Clinical use of bulk drug substances nominated for inclusion on the 503B Bulks List Grant number: 2U01FD005946 Prepared by: University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) University of Maryland School of Pharmacy January 2020 This report was supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award (U01FD005946) totaling $2,342,364, with 100 percent funded by the FDA/HHS. The contents are those of the authors and do not necessarily represent the official views of, nor an endorsement by, the FDA/HHS or the U.S. Government. 1 Table of Contents REVIEW OF NOMINATIONS ................................................................................................... 4 METHODOLOGY ...................................................................................................................
    [Show full text]
  • Effect of 8-Hydroxyquinoline and Derivatives on Human Neuroblastoma SH-SY5Y Cells Under High Glucose
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Crossref Effect of 8-hydroxyquinoline and derivatives on human neuroblastoma SH-SY5Y cells under high glucose Wilasinee Suwanjang1, Supaluk Prachayasittikul2 and Virapong Prachayasittikul3 1 Center for Research and Innovation, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand 2 Center of Data Mining and Biomedical Informatics, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand 3 Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand ABSTRACT 8-Hydroxyquinoline and derivatives exhibit multifunctional properties, including antioxidant, antineurodegenerative, anticancer, anti-inflammatory and antidiabetic activities. In biological systems, elevation of intracellular calcium can cause calpain activation, leading to cell death. Here, the effect of 8-hydroxyquinoline and derivatives (5-chloro-7-iodo-8-hydroxyquinoline or clioquinol and 8-hydroxy-5-nitroquinoline or nitroxoline) on calpain-dependent (calpain-calpastatin) pathways in human neu- roblastoma (SH-SY5Y) cells was investigated. 8-Hydroxyquinoline and derivatives ameliorated high glucose toxicity in SH-SY5Y cells. The investigated compounds, particularly clioquinol, attenuated the increased expression of calpain, even under high- glucose conditions. 8-Hydroxyquinoline and derivatives thus adversely affected the promotion of neuronal cell death by high glucose via the calpain-calpastatin
    [Show full text]
  • In Vivo Evaluation of the Virucidal Efficacy of Chlorhexidine and Povidone-Iodine Mouthwashes Against Salivary SARS-Cov-2
    medRxiv preprint doi: https://doi.org/10.1101/2021.03.07.21252302; this version posted March 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Title: In vivo evaluation of the virucidal efficacy of Chlorhexidine and Povidone-iodine mouthwashes against salivary SARS-CoV-2. Rola Elzein1*, Fadi Abdel-Sater2*, Soha Fakhreddine3, Pierre Abi Hanna3, Rita Feghali4, Hassan Hamad5, Fouad Ayoub6 ¹Department of Pediatric Dentistry and Public Dental Health, Faculty of Dental Medicine, Lebanese University, Beirut, Lebanon 2Laboratory of Cancer Biology and Cellular Immunology, Department of Biological Sciences, Faculty of Sciences, Lebanese University, Beirut, Lebanon 3Infectious Diseases division, Rafik Hariri University Hospital, Beirut, Lebanon 4Department of Laboratory Medicine, Rafik Hariri University Hospital, Beirut, Lebanon 5Medical care Laboratory, Faculty of Public Health IV, Lebanese University, Zahle, Lebanon 6Department of Forensic Odontology, Human Identification and Anthropology, Faculty of Dental Medicine, Lebanese University, Beirut, Lebanon *CORRESPONDING AUTHORS: Rola ELZEIN; Mobile number: 009613252480; Email address: [email protected] Fadi Abdelsater; Mobile number: 009613781176; Email address: [email protected] NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.03.07.21252302; this version posted March 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • A Screening-Based Approach to Circumvent Tumor Microenvironment
    JBXXXX10.1177/1087057113501081Journal of Biomolecular ScreeningSingh et al. 501081research-article2013 Original Research Journal of Biomolecular Screening 2014, Vol 19(1) 158 –167 A Screening-Based Approach to © 2013 Society for Laboratory Automation and Screening DOI: 10.1177/1087057113501081 Circumvent Tumor Microenvironment- jbx.sagepub.com Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia Harpreet Singh1,2, Anang A. Shelat3, Amandeep Singh4, Nidal Boulos1, Richard T. Williams1,2*, and R. Kiplin Guy2,3 Abstract Signaling by the BCR-ABL fusion kinase drives Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myelogenous leukemia (CML). Despite their clinical activity in many patients with CML, the BCR-ABL kinase inhibitors (BCR-ABL-KIs) imatinib, dasatinib, and nilotinib provide only transient leukemia reduction in patients with Ph+ ALL. While host-derived growth factors in the leukemia microenvironment have been invoked to explain this drug resistance, their relative contribution remains uncertain. Using genetically defined murine Ph+ ALL cells, we identified interleukin 7 (IL-7) as the dominant host factor that attenuates response to BCR-ABL-KIs. To identify potential combination drugs that could overcome this IL-7–dependent BCR-ABL-KI–resistant phenotype, we screened a small-molecule library including Food and Drug Administration–approved drugs. Among the validated hits, the well-tolerated antimalarial drug dihydroartemisinin (DHA) displayed potent activity in vitro and modest in vivo monotherapy activity against engineered murine BCR-ABL-KI–resistant Ph+ ALL. Strikingly, cotreatment with DHA and dasatinib in vivo strongly reduced primary leukemia burden and improved long-term survival in a murine model that faithfully captures the BCR-ABL-KI–resistant phenotype of human Ph+ ALL.
    [Show full text]
  • EAR, NOSE and OROPHARYNX Updated: October 2020
    Derbyshire Medicines Management, Prescribing and Guidelines DERBYSHIRE PRIMARY CARE FORMULARY CHAPTER 12: EAR, NOSE AND OROPHARYNX Updated: October 2020 The following prescribing guidelines are relevant to the ENT chapter and can be found here: • Allergic Rhinitis in adults and adolescents over 12 years of age • Management of chronic rhinosinusitis with or without nasal polyps 12.1 DRUGS ACTING ON THE EAR 12.1.1 Otitis externa Investigation is not routinely recommended for the initial diagnosis of otitis externa. Group Drug Astringent/acidic Acetic acid 2% ear spray preparations Self-care: patients are advised to purchase this over the counter Gentamicin 0.3% ear/eye drops* Antibiotic preparations Ciprofloxacin 2mg/ml ear drops 0.25ml unit dose PF Betnesol-N ear/eye/ nose drops* Combined corticosteroid (Betamethasone 0.1% & neomycin 0.5%) and aminoglycoside Otomize ear spray* antibiotic preparations (Dexamethasone 0.1%, neomycin 0.5% & acetic acid 2%) Corticosteroid Prednisolone 0.5% ear/eye drops Lower potency preparations Betamethasone 0.1% ear/eye/ nose drops Higher potency Antifungal preparations Clotrimazole 1% solution 20ml (with dropper) * In view of reports of ototoxicity, manufacturers contra-indicate treatment with topical aminoglycosides in patients with a perforated tympanic membrane (eardrum) or patent grommet. 1. The following are GREY, not for first line empirical use, and should only be used when sensitivity is confirmed through swab results- • Hydrocortisone acetate 1%/gentamicin 0.3% ear drops • Flumetasone pivalate 0.02%/clioquinol 1% ear drops 2. How should I treat acute diffuse otitis externa? (CKS) • Remove or treat any precipitating or aggravating factors. • Prescribe or recommend a simple analgesic for symptomatic relief.
    [Show full text]
  • Expert Recommendations for Prevention, Treatment and Care of Oral Ulcers and Other Mucosal Diseases During the Outbreak of COVID
    Chin J Dent Res 2020;23. Online March 3, 2020. Available at: http://cjdr.cndent.com Expert Recommendations for Prevention, Treatment and Care of Oral Ulcers and other Mucosal Diseases during the Outbreak of COVID-19 Society of Oral Mucosal Diseases, Chinese Stomatological Association1 In December 2019, some new cases of coronavirus disease-19 (COVID-19) were found in Wuhan City, Hubei Province, China. The number of infected cases increased rapidly and spread continuously at home and abroad. Tens of thousands of medical staff throughout the country have rushed to Wuhan to invest in intensive medical treatment. Because of high mental tension and work intensity, unable to drink water for hours after entering the isolation ward and insufficient sleep, they might suffer from oral mucosal ulcers and other oral mucosal diseases. It is known that not only medical staff, but also police officers, community workers, long-term family members, and even patients with mild COVID-19, as well as those with oral mucosal disease in the past, all claim they feel uncomfortable with oral mucosal disorders, such as oral ulcer caused by great mental pressure, which mainly include recurrent aphthous ulcer (RAU), chronic cheilitis and oral lichen planus. This article will give some suggestions on the prevention and care of the oral mucosal diseases above mentioned during fighting againstOnline COVID-19, focusing on the measures First to deal with the oral mucosal damage caused by stress response. Key words: coronavirus disease-19 (COVID-19), recurrent aphthous ulcer, cheilitis, oral lichen planus, stress response 1 Corresponding author: Prof. Hong Wei LIU, Department of Oral Medicine, Peking University School and Hospital of Stomatology, 22# Zhongguancun South Avenue, Haidian District, Beijing 100081, P.R.
    [Show full text]
  • Inactivation of SARS-Cov-2 Through Treatment with the Mouth Rinsing Solutions Viruprox® and Bacterx® Pro
    microorganisms Communication Inactivation of SARS-CoV-2 through Treatment with the Mouth Rinsing Solutions ViruProX® and BacterX® Pro Julia Koch-Heier 1,†, Helen Hoffmann 1,†, Michael Schindler 2 , Adrian Lussi 3,4 and Oliver Planz 1,* 1 Interfaculty Institute for Cell Biology, Department of Immunology, Eberhard Karls University of Tuebingen, 72076 Tuebingen, Germany; [email protected] (J.K.-H.); [email protected] (H.H.) 2 Institute for Medical Virology and Epidemiology of Viral Disease, Department of Molecular Virology, 72076 Tuebingen, Germany; [email protected] 3 Department of Operative Dentistry and Periodontology, University Medical Centre, 79106 Freiburg, Germany; [email protected] 4 School of Dental Medicine, University of Bern, 3010 Bern, Switzerland * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic effects daily dental work. Therefore, infection control measures are necessary to prevent infection of dental personnel during dental treatments. The use of a preprocedural mouth rinse with chlorhexidine (CHX), cetylpyridinium chloride (CPC), or hydrogen peroxide (H2O2) solution for 30–60 s may reduce the viral load and may protect the personnel in a dental practice. In the present study the ® virucidal effect of the mouth rinsing solutions ViruProX with 0.05% CPC and 1.5% H2O2 and Citation: Koch-Heier, J.; Hoffmann, BacterX® pro containing 0.1% CHX, 0.05% CPC, and 0.005% sodium fluoride (F-) was investigated H.; Schindler, M.; Lussi, A.; Planz, O. in vitro. The mouth rinsing solutions successfully inactivated infectious SARS-CoV-2 particles, the Inactivation of SARS-CoV-2 through causative agent of coronavirus disease 2019 (COVID-19), within 30 s.
    [Show full text]
  • Chemical Modulators of Fibrinogen Production and Their Impact on Venous Thrombosis
    Published online: 2020-12-10 Coagulation and Fibrinolysis 433 Chemical Modulators of Fibrinogen Production and Their Impact on Venous Thrombosis Rui Vilar1 Samuel W. Lukowski1,2 Marco Garieri1 Corinne Di Sanza1 Marguerite Neerman-Arbez1,3 Richard J. Fish1 1 Department of Genetic Medicine and Development, University of Address for correspondence Richard J. Fish, Department of Genetic Geneva Faculty of Medicine, Geneva, Switzerland Medicine and Development, Faculty of Medicine, University of 2 Institute for Molecular Bioscience, The University of Queensland, Geneva, 1, rue Michel-Servet, Geneva 1206, Switzerland Saint Lucia, Queensland, Australia (e-mail: [email protected]). 3 iGE3, Institute of Genetics and Genomics in Geneva, Geneva, Switzerland Thromb Haemost 2021;121:433–448. Abstract Thrombosis is a leading cause of morbidity and mortality. Fibrinogen, the soluble substrate for fibrin-based clotting, has a central role in haemostasis and thrombosis and its plasma concentration correlates with cardiovascular disease event risk and a prothrombotic state in experimental models. We aimed to identify chemical entities capable of changing fibrinogen production and test their impact on experimental thrombosis. A total of 1,280 bioactive compounds were screened for their ability to alter fibrinogen production by hepatocyte-derived cancer cells and a selected panel was tested in zebrafish larvae. Anthralin and all-trans retinoic acid (RA) were identified as fibrinogen-lowering and fibrinogen-increasing moieties, respectively. In zebrafish larvae, anthralin prolonged laser-induced venous occlusion times and reduced thrombocyte accumulation at injury sites. RA had opposite effects. Treatment with RA, a nuclear receptor ligand, increased fibrinogen mRNA levels. Using an antisense morpholino oligonucleotide to deplete zebra- fish fibrinogen, we correlated a shortening of laser-induced venous thrombosis times with RA treatment and fibrinogen protein levels.
    [Show full text]